The 1635-EORTC-BTG study - Wait or Treat - concerns patients that represent a clinically
favorable group of patients with IDHmutated astrocytoma (oligo-symptomatic), without a need
for immediate post-operative treatment. It will establish whether early adjuvant treatment
with radiotherapy and adjuvant temozolomide in resected IDHmutated astrocytoma will improve
outcome, and whether benefits of early treatment outweigh potential side-effects of that,
such as deterioration in neurocognitive function or Quality of Live, seizure activity and
Patient Reported outcome compared to active surveillance.
Low Grade Glioma,
Wait or Treat
Clinical Study Identifier
European Organisation for Research and Treatment of Cancer - EORTC
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.